Genotyping the future: Scientists' expectations about race/ethnicity after BiDil

Richard Tutton*, Andrew Smart, Paul A. Martin, Richard Ashcroft, George T.H. Ellison

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The ongoing debate about the FDA approval of BiDil in 2005 demonstrates how the first racially/ethnically licensed drug is entangled in both Utopian and dystopian future visions about the continued saliency of race/ethnicity in science and medicine. Drawing on the sociology of expectations, this paper analyzes how scientists in the field of pharmacogenetics are constructing certain visions of the future with respect to the use of social categories of race/ethnicity and the impact of high-throughput genotyping technologies that promise to transform scientific practices.

Original languageEnglish
Pages (from-to)464-470
Number of pages7
JournalJournal of Law, Medicine and Ethics
Volume36
Issue number3
DOIs
Publication statusPublished - Sept 2008

Cite this